Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Novocure Ltd

NVCR ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Small Cap Analyst: BUY

Last Close

$16.95

▼ -2.47%

Market Cap $1.97B · Vol 245.10K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.97B

Small Cap

Div Yield

N/A

EPS Growth

-11.55%

YoY

RSI (14)

49.42

Momentum

Beta

1.02

vs Market

52W High

$21.33

20.53% below

52W Low

$9.82

72.61% above

Volume

245.10K

Avg 577.71K

P/B

4.27

Price-to-book

ROE

-38.89%

Return on equity

Free Float

90.05%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Novocure Ltd (NVCR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NVCR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.42%

+9.00%

-6.09%

+54.23%

YTD

+31.09%

+46.25%

-45.85%

-87.83%

Financials & Valuation

TTM · Annual

Total Revenue	$655.35M
Net Income	$-136,227,000.00
Revenue Growth (YoY)	+15.60%
Gross Margin	74.54%
Operating Margin	-22.41%
Net Profit Margin	-20.79%
ROE	-38.89%
ROA · ROIC	-13.32% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.20
P/B	4.27
P/FCF	N/A
EPS Growth	-11.55%
Outstanding Shares	116.45M

Technical Indicators

50-Day SMA	$16.43
200-Day SMA	$13.93
RSI (14)	49.42
Beta	1.02
52-Week High	$21.33
52-Week Low	$9.82

Volume Today	245.10K
Avg Daily Volume (30D)	577.71K
Relative Volume	0.42x
Volatility (10D)	49.10
Volatility (30D)	94.49
Free Float	90.05%

Analyst Consensus

BUY

Current Price $16.95

Mean Target $28.83

52W Low$9.82 52W High$21.33

Current

Target

$9.82 $21.33

Current Analyst target

+70.11% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG009XW8QY0

ISINJE00BYSS4X48

CountryJersey

Sub-IndustryMedical Equipment

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

PEN Penumbra Inc +0.08% GETI B.ST Getinge publ AB +0.08% 7747.T Asahi Intecc Co Ltd -0.97% MMED MiniMed Group Inc +0.65% 688617.SS APT Medical Inc +0.14%

Company Profile

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.